Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.

Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD, Stojdl DF, Ungerechts G, Diallo JS, Bell JC.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaao1641. doi: 10.1126/scitranslmed.aao1641.

PMID:
29298865
2.

Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.

Selman M, Rousso C, Bergeron A, Son HH, Krishnan R, El-Sayes NA, Varette O, Chen A, Le Boeuf F, Tzelepis F, Bell JC, Crans DC, Diallo JS.

Mol Ther. 2018 Jan 3;26(1):56-69. doi: 10.1016/j.ymthe.2017.10.014. Epub 2017 Oct 24.

PMID:
29175158
3.

Single-particle characterization of oncolytic vaccinia virus by flow virometry.

Tang VA, Renner TM, Varette O, Le Boeuf F, Wang J, Diallo JS, Bell JC, Langlois MA.

Vaccine. 2016 Sep 30;34(42):5082-5089. doi: 10.1016/j.vaccine.2016.08.074. Epub 2016 Sep 8.

PMID:
27614781
4.

Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing.

Arulanandam R, Batenchuk C, Varette O, Zakaria C, Garcia V, Forbes NE, Davis C, Krishnan R, Karmacharya R, Cox J, Sinha A, Babawy A, Waite K, Weinstein E, Falls T, Chen A, Hamill J, De Silva N, Conrad DP, Atkins H, Garson K, Ilkow C, Kærn M, Vanderhyden B, Sonenberg N, Alain T, Le Boeuf F, Bell JC, Diallo JS.

Nat Commun. 2015 Mar 30;6:6410. doi: 10.1038/ncomms7410.

PMID:
25817275

Supplemental Content

Loading ...
Support Center